Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
- Details
- Category: Pfizer
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases.
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
- Details
- Category: Novartis
Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide.
AstraZeneca divests rights for Losec to Cheplapharm
- Details
- Category: AstraZeneca
AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). The divestment includes medicines containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names.
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman
- Details
- Category: Pfizer
Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has unanimously elected Pfizer's Chief Executive Officer (CEO), Dr. Albert Bourla, to succeed him as Chairman of the Board of Directors effective January 1, 2020. Bourla will also retain the CEO role.
Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial
- Details
- Category: AstraZeneca
New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of dual antiplatelet therapy, Brilinta (ticagrelor) monotherapy (90mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases
- Details
- Category: Bayer
Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases. The joint lab will host scientists from all three parties and Bayer is investing more than USD 30 million to fund joint research projects over the next five years.
More Pharma News ...
- AstraZeneca amends collaboration with Ironwood for Linzess in China
- Educational campaign helps teens and their caregivers tackle the everyday challenges of living with moderate-to-severe atopic dermatitis
- FDA grants Fast Track designation for Farxiga in heart failure
- Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
- Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack
- Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
- Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound